Abstract:Objective: To summarize the clinical features, diagnosis and enzyme replacement therapy(ERT) of Fabry disease (FD) in children. Methods: The clinical data, laboratory tests, genetic variations and treatment of 10 FD children diagnosed in Shandong Provincial Hospital from September 2020 to June 2022 were retrospectively analyzed. Results: Among the 10 cases from 6 families, 7 patients were boys of 4 to 13 years of age, and 3 were girls of 12 to 15 years of age. There were 7 symptomatic patients, including 6 boys and 1 girl. All 7 patients presented with acral neuralgia. Five patients had little or no sweating. Five patients presented with cutaneous angiokeratoma. Two patients had abdominal pain. One patient developed joint symptoms. Four patients had corneal opacity. One patient had hearing loss; one patient had short stature. One patient had mild proteinuria and 1 patient had dysplasia of the right kidney with decreased eGFR (55.28 ml/min.1.73 m 2 ). The left ventricular mass index was slightly elevated in 1 patient. Three patients had mild obstructive ventilatory dysfunction; a small amount of effusion in the intestinal space of the lower abdomen or mild fatty liver was found in 2 patients. Partial empty sella turcica in 1 patient. A total of 6 GLA gene variants were detected in 10 children, among which C.1059_1061delGAT (p.met353del) was a newly discovered mutation. Five children received ERT, of which 4 were treated with agalsidase beta and 1 was treated with agalsidase alpha. Only 1 patient had anaphylaxis. Lyso-GL-3 levels decreased significantly in the first 3 months of ERT initiation and remained relatively stable thereafter in 3 patients. The Lyso-GL-3 level was decreased, but renal impairment continued to progress in 1 patient treated with agalsidase alpha. Conclusion: The clinical manifestations of FD in childhood are diverse, and it is necessary to make a definite diagnosis by combining family history, enzyme activity, biomarkers, gene testing and other indicators. Pedigree screening and high-risk population screening are helpful for early identification, early diagnosis and early treatment. No serious adverse reactions were found during the short-term treatment with agalsidase alpha and beta.

Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy

Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy

Interferon lambda modulates proinflammatory cytokines production in PBMCs from patients with chronic kidney disease

Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process

Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

Clinical features, genetic variations and enzyme replacement therapy in five Chinese patients with Fabry disease

Integrative Systems Biology Investigation of Fabry Disease

Clinical features and enzyme replacement therapy in 10 children with Fabry disease

Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications

Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease

Deep next-generation proteomics and network analysis reveal systemic and tissue-specific patterns in Fabry disease

Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease

Amelioration of Serum 8-Ohdg Level by Enzyme Replacement Therapy in Patients with Fabry Cardiomyopathy.

Plasma and platelet lipidome changes in Fabry disease

Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy

Clinical and Genetic Spectrum in Chinese Families with Fabry Disease: a Single‐centre Case Series

Serum Neopterin, Biopterin, Tryptophan, and Kynurenine Levels in Patients with Fabry Disease

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease

Clinic-Pathologic Features and Renal Outcome of Fabry Disease: Data from a Chinese Cohort.